500 mg deep Ceftriaxone with in 2 ml intramuscular lignocaine 1% injection Treatment recommendations Client STI acquired in Treatment Empirical treatment Goldfields, Kimberley, Uncomplicated of symptomatic ZAP Pilbara gonorrhoea clients + / - Rest of WA and Laboratory or Point chlamydia LAC elsewhere of Care testing confirmed cases Goldfields, Kimberley, Azithromycin Pilbara Uncomplicated Sexual partners of chlamydia Rest of WA and confirmed cases Azithromycin elsewhere Treatment notes Consent to treatment should be obtained, as required, in accordance with local organisational policy Clients should be of advised of expected adverse events and provided with a treatment fact sheet - For clients with a history of allergy to any component of treatment, or other contraindication - do not administer treatment - seek further advice from a medical practitioner For management of any reported adverse events - seek further advice from a medical practitioner Clients should be directly observed while taking oral doses
Ceftriaxone with lignocaine 1% 500 mg in 2 ml deep intramuscular injection Treatment recommendations Client STI acquired in Treatment Empirical treatment of symptomatic clients Uncomplicated gonorrhoea + / - chlamydia Goldfields, Kimberley, Pilbara ZAP Laboratory or Point of Care testing confirmed cases Rest of WA and elsewhere LAC Uncomplicated chlamydia Goldfields, Kimberley, Pilbara Azithromycin Sexual partners of confirmed cases Rest of WA and elsewhere Azithromycin Treatment notes Consent to treatment should be obtained, as required, in accordance with local organisational policy Clients should be of advised of expected adverse events and provided with a treatment fact sheet - For clients with a history of allergy to any component of treatment, or other contraindication - do not administer treatment - seek further advice from a medical practitioner For management of any reported adverse events - seek further advice from a medical practitioner Clients should be directly observed while taking oral doses
SASA_006_2_2018_NUR%20STI.docx